Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Tau Forms in CSF as a Reliable Biomarker for Progressive Supranuclear Palsy
Neurol 71:1796-1803, Borroni,B.,et al, 2008
Diff Diag of parkinson's Disease, Multiple Sys Atrophy, & Steele-Richardson-Olszewski Syndrome:Striatal F-Dopa PET Data
JNNP 57:278-284, Burn,D.J.,et al, 1994
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
Positron Emission Tomography in Progressive Supranuclear Palsy
Arch Neurol 48:389-391, Bhatt,M.H.,et al, 1991
PET Study in Progressive Supranuclear Palsy, Hypometabolic Pattern
Arch Neurol 47:747-752, Blin,J.,et al, 1990
Cerebral Hypometabolism in Progressive Supranuclear Palsy Studied with Positron Emission Tomography
Ann Neurol 24:399-406, Foster,N.L.,et al, 1988